External Source:
COVID-19 and type 1 diabetes | Diabetes Research & Clinical Practice | Volume 166, Issue 108275

“Decreased health budgets could threaten country procurement of essential medicines (such as insulin) and other supplies critical for T1D care, which would both imperil care of indigent individuals with T1D and impede country progress towards universal health coverage of diabetes care[] In response, diabetes centres in various countries are addressing these challenges with courage and innovation.”


In response to the Coronavirus Disease 2019 (COVID-19) pandemic caused by the Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV 2), as of May 2020, almost all nations have enforced strict measures to contain the spread of the virus. These include countrywide lockdowns, whereby internal travel has been restricted and borders have been closed. These measures have severe negative impacts on national economies. COVID-19 is challenging all diabetes services, but the situation is particularly perilous for people with type 1 diabetes (T1D) in Low-and-middle income countries (LMICs). Even in non-pandemic times, access to insulin, blood glucose monitoring, and expert clinical care is often challenging to maintain due to lack of affordable and available provision. Continual access to these components is essential to prevent serious acute complications and deaths.